Table 3.
Univariate and multivariate Cox proportional regression analysis of factors associated with TNFi discontinuation in patients with RA.
| Univariate | Multivariate (model 1)† | Multivariate (model 2)‡ | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| Age | 0.99 | 0.97–1.03 | ||||
| Disease duration (year) | 0.99 | 0.90–1.08 | ||||
| BMI | 0.92 | 0.81–1.05 | ||||
| Baseline erosions of hands or feet | 2.19* | 1.00–4.77 | 2.45* | 1.08–5.51 | ||
| Baseline JSN of hands or feet | 2.17* | 1.00–4.68 | 2.22 | 0.97–5.10 | ||
| Baseline PtGA (0–100) | 1.03*** | 1.01–1.04 | 1.02 | 0.99–1.04 | 1.01 | 0.99–1.03 |
| Baseline PhGA (0–100) | 1.04*** | 1.02–1.06 | 1.01 | 0.99–1.04 | 1.02 | 0.99–1.04 |
| Baseline Td joint (yes) | 0.37 | 0.09–1.57 | ||||
| Baseline swollen joint (yes) | 0.27 | 0.06–1.14 | ||||
| Time-averaged DAS28 | 2.93*** | 2.09–4.11 | 2.17*** | 1.47–3.20 | 2.28*** | 1.52–3.41 |
| Time-averaged HAQ | 2.79*** | 1.66–4.69 | 1.19 | 0.55–2.56 | 1.03 | 0.48–2.18 |
| Smoking | ||||||
| Nonsmoker | (reference) | |||||
| Ex-smoker | NA | |||||
| Current smoker | 0.70 | 0.09–5.17 | ||||
| Regular exercise (yes) | 1.55 | 0.72–3.35 | ||||
| Rheumatoid factor positive | 1.00 | 0.38–2.66 | ||||
| ACPA positive | 1.37 | 0.55–3.40 | ||||
| Baseline ESR (mm/h) | 1.02*** | 1.01–1.04 | ||||
| Baseline CRP (mg/dL) | 1.04 | 0.88–1.23 | ||||
| Previous bDMARDs use | 0.87 | 0.26–2.89 | ||||
| Etanercept (compared to adalimumab) | 0.70 | 0.32–1.50 | ||||
| Methotrexate | 0.31** | 0.14–0.69 | 0.40* | 0.17–0.95 | 0.44 | 0.18–1.08 |
| Glucocorticoid dose (mg/day, equivalent to prednisolone) | 1.04 | 0.88–1.24 | ||||
| NSAID | 1.37 | 0.41–4.58 | ||||
| Female sex | NA | |||||
HR hazard ratio, CI confidence interval, RA rheumatoid arthritis, BMI body mass index, JSN joint space narrowing, NSAID nonsteroidal anti-inflammatory drug, bDMARDs biological disease-modifying antirheumatic drugs, TNFi tumor necrosis factor inhibitor, CRP C-reactive protein, ESR erythrocyte sedimentation rate, RF rheumatoid factor, ACPA anticitrullinated protein antibody, PhGA physician’s global assessment, PtGA patient’s global assessment, DAS28 disease activity score 28, HAQ health assessment questionnaire.
*p < 0.05, **p < 0.01, ***p < 0.001.
†All variables with p-values < 0.05 in univariate Cox regression analyses, except for JSN, were included in multivariate analysis.
‡All variables with p-values < 0.05 in univariate Cox regression analyses, except for erosions, were included in multivariate analysis.